

Simple Solutions for Patient Monitoring

What is the interest of having a high level of sensitivity ?

Higher sensitivity means you are able to offer better patient monitoring, particularly in the low viral load values. This ensures patients can benefit from enhanced quality of life through better adapted therapy and rapid detection of resistance to treatment.

Why is flexibility important ?

A test that is flexible will adapt more readily to the needs of the different types of laboratories and patients. It ensures you will be able to monitor patients using the same technology and platform whatever the setting or lab configuration. Teamed with Dry Blood Spot (DBS), a simple, safe transport medium, viral load monitoring of patients in remote areas is now possible enabling patients who could previously not be monitored to receive treatment.

Maximum Flexibility

- ➔ Configuration: 8 to 1000 viral load tests/day
- ➔ Sample: Plasma/DBS





BOOM[®] 1
The Gold Standard
in efficient nucleic acid
extraction



NASBA[®] 1, 2
Real-time Amplification
& Detection
Isothermal : 41°C



Time < 3 hrs



1- bioMérieux's proprietary technology.
2- NASBA: Nucleic Acid Sequence Based Amplification.

NucliSENSTM EasyQ HIV-1 V2.0 Performance

High Level of Sensitivity

Sample Volumes

NucliSENS EasyQ[®] HIV-1 v2.0:
validated input volumes plasma and DBS


Claimed LoD (95% detection level)

Flexible Input	Limit of Detection (LoD)
1 ml plasma	25 cps/ml*
0.5ml plasma	50 cps/ml*
0.1 ml plasma	292 cps/ml*
Dry Blood Spot (0.1 ml)	802 cps/ml


* Performance still subject to regulatory approval

Correlation

**NucliSENS EasyQ HIV v1.2 and
NucliSENS EasyQ HIV 2.0 on EDTA plasma**



**NucliSENS EasyQ HIV 2.0 on plasma
versus NucliSENS EasyQ HIV 2.0 on DBS**



Test Features

Subtypes:

A, B, C, D, F, G, H, J, CRF01_AE and CRF02_AG

Measuring range:

10-10 000 000 copies/ml

Sample:

0.1 - 0.5 - 1 ml human plasma and DBS

Why Choose NucliSENS EasyQ[®] HIV-1 V2.0 ?

➔ Rapid, Simple Results

Turn-around-time from sample to result is **< 3 hours per run**, with less than 1 hour hands-on time, allowing fast reporting and optimal workflow planning. Results are also expressed clearly and simply.

➔ Sensitive Testing

The unrivaled, proprietary magnetic BOOM[®] extraction combined with the highly efficient real-time NASBA[®] reaction of only one hour ensures very sensitive test results.

➔ Flexible And Scalable

The NucliSENS system configuration is fully adaptable to individual laboratory needs with a testing capability going from 8 up to over 1000 tests per day per technician with extraction being performed on either the manual NucliSENS[®] miniMAG[®] or automated NucliSENS[®] easyMAG[®]. Both plasma and DBS samples can be used ensuring both routine and remote patient monitoring can be performed.

➔ Internally Calibrated

Reliable and accurate quantification is achieved through an individual, internal calibrator that is already added at the sample lysis step. This calibrator validates each sample making external controls superfluous.

➔ Space Saving & No Contamination

The NucliSENS EasyQ system fits easily into every laboratory and is a closed system preventing contamination.



From the very beginning... bioMérieux – your innovative partner in HIV testing

2009

NucliSENS EasyQ® HIV-1 v2.0
Real-time HIV viral load using plasma and Dry Blood Spot

VIDIA® HIV DUO

4th generation automated test

Vironostika® HIV Ag/Ab

4th generation microplate screening test

2007

VIKIA™ HIV 1/2

Simple hand-held device for rapid testing

2004

VIDAS® HIV DUO Ultra

VIDAS® HIV DUO Quick

Advanced 4th generation automated tests

2002

NucliSENS EasyQ® HIV-1

First real-time HIV-1 viral load assay

1998

VIDAS® HIV DUO

First 4th generation automated test

Vironostika® HIV Uni-Form II Ag/Ab

First 4th generation microplate test

1995

Vironostika® HIV Uni-Form II plus O

Group O detection

NASBA® HIV-1 QT

First HIV-1 viral load assay

1994

VIDAS® HIV P24 Ag

Quantitative Ag detection in automated format

1993

VIDAS® HIV-1 anti P24

First automated HIV-1 p24 Ab test

NucliSENS® HIV-1 QL

Qualitative HIV-1 RNA

1992

Vironostika® HIV Uni-Form II

3rd generation microplate test

1991

VIDAS® HIV-1+2

First automated HIV assay

1989

Vironostika® HIV MIXT

HIV-1 and HIV-2 detection

1988

Vironostika® HIV-1 Antigen

p24 antigen detection

1987

Vironostika® HIV Uni-Form

One-step microElisa assay

1985

Vironostika® anti-HTLV III

First screening tests available

1983

Discovery of the virus

Committed to the fight for 25 years

Your Concern  Our Commitment

bioMérieux's commitment to HIV testing started 25 years ago, at the very beginning of the epidemic. Our research teams developed one of the first screening tests available in 1985, following the discovery of the HIV virus.

Today, bioMérieux diagnostics play an essential role in HIV management, for screening, preventing mother-to-child transmission and improving patient care. We are committed to making innovation in HIV testing accessible to all types of healthcare settings and systems.

To further this goal, bioMérieux will bring viral load monitoring to patients in remote areas through one of the latest breakthroughs in HIV testing, the Dry Blood Spot.

NucliSENS[™] EasyQ HIV-1 V2.0

Ref: 28 5033 (48 tests)

Ref: 28 5043 (480 tests)

A COMPLETE RANGE

Prevention and Diagnosis

- VIKIA[™] HIV 1/2
- VIDAS[®] HIV DUO ULTRA
- VIDAS HIV DUO QUICK
- VIDAS HIV P24 II
- VIDAS HIV P24 II Confirmation
- Vironostika[®] HIV Uniform II plus 0
- Vironostika HIV Ag/Ab
- VIDIA[®] HIV DUO

Monitoring

- NucliSENS EasyQ[®] HIV-1 v2.0



Some of these reagents are under development or have not yet obtained regulatory clearance in some countries. Please contact your local bioMérieux representative for further information and product availability.

bioMérieux S.A.
69280 Marcy l'Etoile
France
Tél. : 33 (0)4 78 87 20 00
Fax : 33 (0)4 78 87 20 90

www.biomerieux-diagnostics.com/hiv
www.biomerieux.com


 BIOMÉRIEUX

H I V I N F E C T I O N

PREVENTION

DIAGNOSIS

MONITORING



NucliSENS™ **HIV-1** **V2.0**
EasyQ

Simple Solutions
for Patient Monitoring


BIOMÉRIEUX